Heart failure & cardiomyopathies
Pilot Trial of an Electronic Decision Support to Improve Care for Emergency Department Patients with Acute Heart Failure
Authors' conclusion
Ongoing treatment with GDMT at ED arrival was sub-optimal. Initiation among appropriate patients at discharge may be feasible and safe.
Study context
- Population
- Emergency department (ED) patients treated for acute HF and discharged from the ED or ED-based observation unit, 2 EDs, 1 January–31 July 202336 (15.4%) missing EF
- Participants
- 234 patients
- Comparison
- HFrEF vs HFmrEF vs HFpEF
- HFrEFn = 51
- HFmrEFn = 21
- HFpEFn = 126
- Outcome
- Active prescriptions for the 4 guideline directed medical therapy (GDMT) classes (beta-blockers (BBs), RASis, SGLT2is, mineralocorticoid receptor antagonists (MRA)) among HFrEF and HFmrEF patients
- Follow-up
- ED arrival and ED discharge
Methodological details2 EDs
- 2 EDs
Main finding
As reported in the abstract
GDMT prescription at ED arrival
| Outcome | HFrEF | HFmrEF | HFpEF |
|---|---|---|---|
| RASi | 68.6% | 42.9% | — not stated in the abstract |
| BB | 66.7% | 66.7% | — not stated in the abstract |
| SGLT2i | 25.5% | 14.3% | 6 (4.8%) |
| MRA | 19.6% | 4.8% | — not stated in the abstract |
— not stated in the abstract
Safety
30-day serious adverse events (SAE) (death, CPR, balloon-pump insertion, intubation, new dialysis, MI or coronary revascularization) in very-low-risk patients discharged home
- No 30-day SAE among the 51 patients predicted very low risk by STRIDE-HF and discharged home
Original publication
Pilot Trial of an Electronic Decision Support to Improve Care for Emergency Department Patients with Acute Heart Failure. ESC Heart Fail. Published 25 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →